Reuters logo
BRIEF-Rigel provides update on FDA review of fostamatinib for ITP
October 2, 2017 / 11:46 AM / 2 months ago

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

Oct 2 (Reuters) - Rigel Pharmaceuticals Inc

* Rigel provides update on FDA review of fostamatinib for ITP

* Rigel Pharmaceuticals - FDA indicated that, at this point, it is not planning to hold an oncology drugs advisory committee meeting to discuss NDA for fostamatinib​

* Rigel Pharmaceuticals Inc - FDA indicated it anticipates meeting PDUFA action date for application review, which is April 17, 2018

* Rigel Pharmaceuticals Inc - FDA indicated that it anticipates meeting PDUFA action date for application review, which is April 17, 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below